The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma

BACKGROUND: In solid tumor Phase 1/2 trials (NCT02407990; NCT04068519), tislelizumab demonstrated clinical benefit, including in advanced gastroesophageal adenocarcinoma (GEA). However, the majority of patients with GEA did not respond, highlighting the need to understand mechanisms of resistance an...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Zhihao, Yang, Silu, Luo, Xuerui, Shi, Yang, Lee, Jong-Seok, Deva, Sanjeev, Liu, Tianshu, Chao, Yee, Zhang, Yun, Huang, Ruiqi, Xu, Yaling, Shen, Zhirong, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365737/
https://www.ncbi.nlm.nih.gov/pubmed/35778636
http://dx.doi.org/10.1007/s10120-022-01308-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365737/
https://www.ncbi.nlm.nih.gov/pubmed/35778636
http://dx.doi.org/10.1007/s10120-022-01308-7

Ejemplares similares